Tenth generic of thrombopoietin drug Revolade to enter Russian market - GxP News

Tenth generic of thrombopoietin drug Revolade to enter Russian market  GxP News

Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytop...

Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder  Novartis

GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe a...

GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe aplastic anaemia  GSK

Long-term safety data for Revolade in adults with chronic ITP - European Pharmaceutical Review

Long-term safety data for Revolade in adults with chronic ITP  European Pharmaceutical Review

Generic Medicine OKd by Europe for Thrombocytopenia With HCV - Medscape

Generic Medicine OKd by Europe for Thrombocytopenia With HCV  Medscape

Type Analysis - Market.us

Type Analysis  Market.us

Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with s...

Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia  Novartis

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia - The New England Journal of Med...

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia  The New England Journal of Medicine

Novartis’ Revolade proved effective for seniors - koreabiomed.com

Novartis’ Revolade proved effective for seniors  koreabiomed.com

NICE thumbs-up for Revolade - Pharmafile

NICE thumbs-up for Revolade  Pharmafile

GSK receives marketing authorisation from the European Commission for additional Revolade - GSK

GSK receives marketing authorisation from the European Commission for additional Revolade  GSK

EU approval for Revolade for paediatric patients with chronic ITP - European Pharmaceutical Review

EU approval for Revolade for paediatric patients with chronic ITP  European Pharmaceutical Review

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia - koreabiomed.com

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia  koreabiomed.com

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other...

Real-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapies  Novartis

Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Re...

Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Revolade  GSK

Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocyto...

Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)  Novartis

GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepat...

GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection  GSK

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designati...

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication  Novartis

Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplasti...

Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder  Novartis

Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year an...

Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP  Novartis

NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment i...

NIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemia  Novartis

Novartis bags EU approvals for three ex-GSK drugs - PMLiVE

Novartis bags EU approvals for three ex-GSK drugs  PMLiVE

Novartis' patent on eltrombopag olamine upheld by Delhi High Court - The Pharma Letter

Novartis' patent on eltrombopag olamine upheld by Delhi High Court  The Pharma Letter

GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic sy...

GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes  GSK

GSK guilty of off-label promotion - Pharmafile

GSK guilty of off-label promotion  Pharmafile

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA) - Nov...

FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)  Novartis

NICE says yes to Grifols' Tavlesse for rare blood disorder ITP - pharmaphorum

NICE says yes to Grifols' Tavlesse for rare blood disorder ITP  pharmaphorum

New hope for ITP patients dashed by high drug cost - CBC

New hope for ITP patients dashed by high drug cost  CBC

Novartis: Blood Disease Drugs Jakavi, Revolade Show Positive Study Results - finchannel

Novartis: Blood Disease Drugs Jakavi, Revolade Show Positive Study Results  finchannel

GSK’s Promacta extends US licence - Pharmafile

GSK’s Promacta extends US licence  Pharmafile

Promacta receives Breakthrough Therapy designation for SAA - European Pharmaceutical Review

Promacta receives Breakthrough Therapy designation for SAA  European Pharmaceutical Review

FDA expands use of eltrombopag - MDEdge

FDA expands use of eltrombopag  MDEdge

Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in sever...

Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)  Novartis

Promacta Side Effects Can Lead To Fatal Liver Injuries, Health Canada Warns - AboutLawsuits.com

Promacta Side Effects Can Lead To Fatal Liver Injuries, Health Canada Warns  AboutLawsuits.com

How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17 - Market Realist

How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17  Market Realist

Govt to fund drug for rare blood disorder - NZ Herald

Govt to fund drug for rare blood disorder  NZ Herald

Drug Patents and their Evergreening Conundrum - Bar and Bench

Drug Patents and their Evergreening Conundrum  Bar and Bench